RxDoctor Payments Data

Haifa Alrawi

Family · Livonia, MINPI 1699410605

Payments from drug & device makers

$1,293in general payments, 2019–2025

Across 14 payments — averaging $92.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$300
  • Boehringer Ingelheim$249
  • Novo Nordisk$236
  • Exact Sciences$141
  • Phathom Pharmaceuticals, Inc.$125
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
  • plus $118 from 2 others

What the payments were for

  • Food & beverage$1,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,293 in reported general payments places this provider in the 75th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$19,524
Medicare patients
86
Services billed
264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$38,952
TrulicityDulaglutide19$17,254
JanuviaSitagliptin Phosphate19$14,603
EliquisApixaban15$8,885
Breo ElliptaFluticasone/Vilanterol14$5,340
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,067
Albuterol Sulfate HfaAlbuterol Sulfate33$1,021
Diclofenac Sodium44$1,006
Ventolin HfaAlbuterol Sulfate16$889
Atorvastatin Calcium94$482
Metformin Hcl86$350
Lisinopril74$310
Fluticasone Propionate31$301
Levothyroxine Sodium45$284
Metoprolol Succinate25$235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$249$38,95256 claims
Lilly USA, LLCTrulicity$300$17,25419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,657 family providers in Michigan.

Other family in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →